Article Contents ::
- 1 The Brand Name CELGEM Has Generic Salt :: Gemcitabine
- 2 CELGEM Is From Company Cytomed(Alkem) Priced :: Rs. 1332
- 3 CELGEM have Gemcitabine is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name CELGEM Has Generic Salt :: Gemcitabine
CELGEM Is From Company Cytomed(Alkem) Priced :: Rs. 1332
CELGEM have Gemcitabine is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Gemcitabine | VIAL | Rs. 1332 | 1 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 1 |
| CELGEM | Cytomed(Alkem) | 200MG | 1 | Rs. 1332 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Cytomed(Alkem) :: CELGEM | Gemcitabine | #N/A | #N/A |
Indications for Drugs ::
Lung cancer, pancreatic cancer, bladder cancer, breast cancer, ovarian carcinoma
Drug Dose ::
Adult: IV Advanced non-small cell lung cancer 1 g/m2 on days 1, 8 and 15 of each 28-day cycle. Pancreatic cancer 1 g/m2 once wkly for up to 7 wk followed by 1 wk of rest. Continue thereafter w/ once wkly infusions for 3 consecutive wk out of 4. Bladder cancer 1 g/m2 on days 1, 8 and 15 of each 28-day cycle. To be given before cisplatin. Breast cancer 1.25 g/m2 on days 1 and 8 of each 21-day cycle. Ovarian carcinoma 1 g/m2 on days 1 and 8 of each 21-day cycle. To be given before carboplatin.
Contraindication ::
Concurrent radical radiotherapy; pregnancy, lactation; hypersensitivity.
Drug Precautions ::
Children, hepatic and renal impairment. May impair ability to drive or operate machinery. Discontinue on 1st sign of microangiopathic haemolytic anaemia. Prolonged infusion time (>60 minutes) and more frequent than wkly dosing may increase toxicity. Monitor CBC before every dose. Increased risk of haemolytic uraemic syndrome and/or thrombocytcpenic purpura which may lead to irreversible renal failure.
Drug Side Effects ::
Bone marrow suppression as manifested by leukopenia, thrombocytopenia, anaemia and myelosuppression. Mild GI effects; rashes; renal impairment, pulmonary toxicity, influenza-like symptoms; interstitial pneumonia, pulmonary oedema. Proteinuria, haematuria and haemolytic uraemic syndrome. Elevation of serum transaminase. Potentially Fatal: Oesophagitis and pneumonitis when given with radical radiotherapy to the thorax.
Pregnancy category ::
4
Drug Mode of Action ::
Gemcitabine is a synthetic pyrimidine nucleoside and cytarabine analogue which is metabolised intracellularly to active diphosphate and triphosphate nucleosides. It inhibits DNA synthesis by inhibiting DNA polymerase and ribonucleotide reductase. It also induces apoptosis and is primarily active against cells in the S-phase, but may also arrest cells at the G1-S border.
Drug Interactions ::
May increase the anticoagulant effect of warfarin when used together.
